Search

Displaying results 3511 - 3520 of 10000 in total
  1. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Hypophosphatasia is almost always fatal when severe skeletal disease is obvious at birth. … Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.

    Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET
  2. Drug

    Cellobiose

    go.drugbank.com/drugs/DB02061
    Experimental

    A disaccharide consisting of two glucose units in beta (1-4) glycosidic linkage. Obtained from the partial hydrolysis of cellulose. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  4. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. … In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity.

  5. Drug

    Clobetasol

    go.drugbank.com/drugs/DB11750
    ApprovedInvestigationalWithdrawn

    Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

    Categories: Corticosteroids, Very Potent (Group IV)
  6. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.

  7. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra. … Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer.

  8. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression

    Categories: Histocompatibility Antigens Class I
  9. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.

  10. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo.